{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chi X"],"funding":["Natural Science Foundation of Jiangsu Province"],"pagination":["4753-4765"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6712469"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["8(10)"],"pubmed_abstract":["<h4>Background aims</h4>Chimeric antigen receptor T cells (CAR-T cells) have been successfully used in treatments of hematological tumors, however, their anti-tumor activity in solid tumor treatments was limited. As IL-12 increases T-cell immune functions, we designed carcinoembryonic antigen (CEA) specific CAR-T (CEA-CAR-T) cells and, for the first time, used them in combination with recombinant human IL-12 (rhIL-12) to treat several types of solid tumors.<h4>Methods</h4>In vitro anti-tumor activity of CEA-CAR-T cells in combination with rhIL-12 was confirmed by evaluation of CEA-CAR-T cell activation, proliferation, and cytotoxicity after co-incubation with CEA-positive or CEA-negative human tumor cells. In vivo anti-tumor activity of CEA-CAR-T cells in combination with rhIL-12 was confirmed in a xenograft model in nude mice for treatments of several types of solid tumors.<h4>Results</h4>In vitro experiments confirmed that rhIL-12 significantly increased the activation, proliferation, and cytotoxicity of CEA-CAR-T cells. Similarly, in vivo experiments found that CEA-CAR-T cells in combination with rhIL-12 had significantly enhanced anti-tumor activity than CEA-CAR-T cells in growth inhibition of newly colonized colorectal cancer cell HT-29, pancreatic cancer cell AsPC-1, and gastric cancer cell MGC803.<h4>Conclusions</h4>These works confirmed that simultaneous use of cytokines, for example, rhIL-12, can increase the anti-tumor activity of CAR-T cells, especially for treatments of several types of solid tumors."],"journal":["Cancer medicine"],"pubmed_title":["Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12."],"pmcid":["PMC6712469"],"funding_grant_id":["BK20160757"],"pubmed_authors":["Li X","Zhang E","Hu J","Zhang Y","Yang P","Gu J","Gao X","Chi X","Xu H","Li M"],"additional_accession":[]},"is_claimable":false,"name":"Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12.","description":"<h4>Background aims</h4>Chimeric antigen receptor T cells (CAR-T cells) have been successfully used in treatments of hematological tumors, however, their anti-tumor activity in solid tumor treatments was limited. As IL-12 increases T-cell immune functions, we designed carcinoembryonic antigen (CEA) specific CAR-T (CEA-CAR-T) cells and, for the first time, used them in combination with recombinant human IL-12 (rhIL-12) to treat several types of solid tumors.<h4>Methods</h4>In vitro anti-tumor activity of CEA-CAR-T cells in combination with rhIL-12 was confirmed by evaluation of CEA-CAR-T cell activation, proliferation, and cytotoxicity after co-incubation with CEA-positive or CEA-negative human tumor cells. In vivo anti-tumor activity of CEA-CAR-T cells in combination with rhIL-12 was confirmed in a xenograft model in nude mice for treatments of several types of solid tumors.<h4>Results</h4>In vitro experiments confirmed that rhIL-12 significantly increased the activation, proliferation, and cytotoxicity of CEA-CAR-T cells. Similarly, in vivo experiments found that CEA-CAR-T cells in combination with rhIL-12 had significantly enhanced anti-tumor activity than CEA-CAR-T cells in growth inhibition of newly colonized colorectal cancer cell HT-29, pancreatic cancer cell AsPC-1, and gastric cancer cell MGC803.<h4>Conclusions</h4>These works confirmed that simultaneous use of cytokines, for example, rhIL-12, can increase the anti-tumor activity of CAR-T cells, especially for treatments of several types of solid tumors.","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Aug","modification":"2024-11-09T19:30:08.835Z","creation":"2019-09-08T07:01:00Z"},"accession":"S-EPMC6712469","cross_references":{"pubmed":["31237116"],"doi":["10.1002/cam4.2361"]}}